One platform. Two continents.
GenREY is engineered from day one as a U.S. ↔ GCC corridor — research and capital fluency in the West, manufacturing localisation and sovereign deployment in the GCC.
American biotechnology has unmatched depth in early-stage discovery, capital markets and trial infrastructure. The GCC has unmatched ambition in life-sciences sovereignty, manufacturing localisation and patient-recruitment scale. Most companies pick one. We are built to operate across both — natively, not as an afterthought partnership.
On the U.S. side our base is Houston / Texas, anchored by deep relationships across academic medical centres, surgical specialties and the Allegheny / Drexel / U Miami Miller research network. On the GCC side we operate across Saudi Arabia, Qatar and the UAE — aligned to Vision 2030, NEOM, Qatar's life-sciences pivot and the UAE's biotech corridor.
The dual-hub architecture isn't just geography — it's IP filings designed to be portable, manufacturing playbooks designed to localise, clinical protocols designed to harmonise across FDA / SFDA / DHA, and a leadership team that has actually shipped trials in both regions. Sovereignty is engineered, not declared.
U.S. innovation, deployed at sovereign GCC scale.
GenREY runs as two synchronized hubs: a U.S. innovation engine (research, IP, early commercialization) feeding a GCC sovereign deployment hub (manufacturing, clinical adoption, capacity building).
Research · IP · Early commercialization
- · Houston · Texas Rio Grande Valley
- · UT Health · Hidalgo County HHS
- · Translational science engine
- · Regulatory navigation (FDA pathway)
IP licensing · Tech transfer · Clinical reciprocity · Manufacturing localization
Manufacturing · Deployment · Capacity
- · Riyadh · Jeddah · Doha · Abu Dhabi
- · Ministry of Health · KAUST · NTI
- · Sovereign data infrastructure
- · Vision-2030 aligned localization
Sovereign capability
IP, data and manufacturing built within the GCC — reducing reliance on foreign providers and aligning with Vision 2030, the UAE National Strategy for Advanced Innovation, and Qatar National Vision 2030.
Closed-loop translation
A dual-engine model: a grant-funded scientific engine generating IP, paired with a commercial translation engine deploying clinical and consumer products.
Vertical integration
Discovery → IP → Validation → Clinical → Manufacturing → Deployment — under one regenerative platform optimized for sovereign-scale execution.
Recurring economics
Premium device sales, consumable serum/cartridge subscriptions, medspa partnerships, licensing and white-label biotech revenue — built for durable cashflow.
What this enables.
A dual-hub platform unlocks specific commercial and sovereign capabilities.